<DOC>
	<DOCNO>NCT00129844</DOCNO>
	<brief_summary>The purpose study determine effect MGd non-small-cell lung cancer ( NSCLC ) give alone , evaluate difference two dosing regimen .</brief_summary>
	<brief_title>Study Motexafin Gadolinium ( MGd ) Second Line Treatment Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description>Outline : Two-arm , open-label , randomize , 2-stage Phase II trial . Patients randomize first stage 1 2 treatment arm : Arm A - 10 mg/kg MGd per week Arm B - 15 mg/kg MGd every 3 week Patients treat 3 week cycle , maximum 8 cycle ( 24 week ) . Patients either objective response stable disease 2 cycle receive 8 cycle therapy . Patients progressive disease terminate study . At end Stage I , treatment arm evaluate , arm ( ) demonstrate least one response ( Complete Response Partial Response ) proceed Stage II . If arm demonstrate response , proceed Stage II .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>&gt; 18 year old Histologically cytologically confirm diagnosis NSCLC Unresectable locally advance ( Stage IIIB ) metastatic ( Stage IV ) NSCLC patient receive one prior platinumbased chemotherapy regimen Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ECOG performance status score 0 1 Willing able provide write informed consent Laboratory value : Absolute neutrophil count &lt; 1500/ul ; Platelet count &lt; 75,000/ul ; Hemoglobin &lt; 10 gm/dl ; AST ALT &gt; 3 x upper limit normal ( ULN ) ; Alkaline phosphatase &gt; 5 x ULN ; Bilirubin &gt; 2 x ULN ; Serum creatinine &gt; 2.0 mg/dL . Symptomatic uncontrolled ( untreated treat progressing ) brain metastasis . Evidence meningeal metastasis . Greater one prior cytotoxic regimen ( count adjuvant neoadjuvant cytotoxic chemotherapy complete &gt; 12 month prior cytotoxic regimen ) . Chemotherapy , radiation therapy , experimental therapy , immunotherapy systemic biologic anticancer therapy within 21 day begin study treatment . Significant weight loss &gt; 10 % body weight precede 6 week . Treatment another cancer within 3 year enrollment , unless basal cell carcinoma cervical cancer situ . Myocardial infarction within 6 month enrollment congestive heart failure rat New York Heart Association ( NYHA ) Class III IV . Uncontrolled hypertension ( systolic blood pressure &gt; 160 mm Hg diastolic blood pressure &gt; 110 mm Hg maximal medical therapy ) . Known history porphyria ( test require screening visit ) . Known history glucose6phosphate dehydrogenase ( G6PD ) deficiency ( test require screening visit ) . Known history HIV infection ( test require screening visit ) . Female pregnant lactating ( serum pregnancy test require female patient childbearing potential ) . Sexually active male female childbearing potential unwilling use adequate contraceptive protection . Physical mental condition make patient unable complete specify followup assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Motexafin Gadolinium</keyword>
	<keyword>non-small cell , lung cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>cancer lung</keyword>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
</DOC>